Zydus Cadila receives USFDA's final approval to market sedative injection
The injection will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad28-02-2018
Zydus Cadila receives USFDA's final approval to market sedative injection
The injection will be manufactured at the group's formulations manufacturing facility at Moraiya, AhmedabadAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Dexmedetomidine Hydrochloride InjectionAnnouncement under Regulation 30 (LODR)-Press Release / Media Release
'Cadila Healthcare's Moraiya facility successfully completes USFDA inspection.'Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share
Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of thesePress Release On The Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2017.
Press Release on the unaudited financial results for the quarter / nine months ended on December 31, 2017.Financial Results For The Quarter / Nine Months Ended 31/12/2017.
Financial Results for the quarter / nine months ended 31/12/2017.Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd on February 07, 2018, with reference to news appeared in www.bloombergquint.com dated February 07, 2018 quoting "U.S. FDA Conducts Surprise Audit At Cadila's Moraiya Plant". The reply is awaited.Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a conference call on February 8, 2018 at 4:00 p.m., post announcement of unaudited financial results for the quarter / nine months ended on December 31, 2017.Cadila Healthcare turns focus on vaccines and biosimilars
Analysts expect the two segments to contribute 25% of domestic revenue in 2 years; vaccines contribute less than 1% of revenues at present, while biosimilars account for 4.5% of domestic revenues